|
1
|
Vanderkerken K, Asosingh K, Croucher P and
Van Camp B: Multiple myeloma biology: lessons from the 5TMM models.
Immunol Rev. 194:196–206. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Palumbo A and Anderson K: Multiple
myeloma. N Engl J Med. 364:1046–1060. 2011. View Article : Google Scholar
|
|
3
|
Kyle RA, Gertz MA, Witzig TE, Lust JA,
Lacy MQ, Dispenzieri A, Fonseca R, Rajkumar SV, Offord JR, Larson
DR, et al: Review of 1027 patients with newly diagnosed multiple
myeloma. Mayo Clin Proc. 78:21–33. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Krause A, Neitz S, Mägert HJ, Schulz A,
Forssmann WG, Schulz-Knappe P and Adermann K: LEAP-1, a novel
highly disulfide-bonded human peptide, exhibits antimicrobial
activity. FEBS Lett. 480:147–150. 2000.
|
|
5
|
Nemeth E and Ganz T: Regulation of iron
metabolism by hepcidin. Annu Rev Nutr. 26:323–342. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Valore EV and Ganz T: Posttranslational
processing of hepcidin in human hepatocytes is mediated by the
prohormone convertase furin. Blood Cells Mol Dis. 40:132–138. 2008.
View Article : Google Scholar
|
|
7
|
Nemeth E, Tuttle MS, Powelson J, Vaughn
MB, Donovan A, Ward DM, Ganz T and Kaplan J: Hepcidin regulates
cellular iron efflux by binding to ferroportin and inducing its
internalization. Science. 306:2090–2093. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tomosugi N, Kawabata H, Wakatabe R,
Higuchi M, Yamaya H, Umehara H and Ishikawa I: Detection of serum
hepcidin in renal failure and inflammation by using ProteinChip
System. Blood. 108:1381–1387. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kemna E, Tjalsma H, Laarakkers C, Nemeth
E, Willems H and Swinkels D: Novel urine hepcidin assay by mass
spectrometry. Blood. 106:3268–3270. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ganz T, Olbina G, Girelli D, Nemeth E and
Westerman M: Immunoassay for human serum hepcidin. Blood.
112:4292–4297. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ashby DR, Gale DP, Busbridge M, Murphy KG,
Duncan ND, Cairns TD, Taube DH, Bloom SR, Tam FW, Chapman RS, et
al: Plasma hepcidin levels are elevated but responsive to
erythropoietin therapy in renal disease. Kidney Int. 75:976–981.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Schwarz P, Strnad P, von Figura G,
Janetzko A, Krayenbühl P, Adler G and Kulaksiz H: A novel
monoclonal antibody immunoassay for the detection of human serum
hepcidin. J Gastroenterol. 46:648–656. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kulaksiz H, Gehrke SG, Janetzko A, Rost D,
Bruckner T, Kallinowski B and Stremmel W: Pro-hepcidin: expression
and cell specific localisation in the liver and its regulation in
hereditary haemochromatosis, chronic renal insufficiency, and renal
anaemia. Gut. 53:735–743. 2004. View Article : Google Scholar
|
|
14
|
Kemna E, Pickkers P, Nemeth E, van der
Hoeven H and Swinkels D: Time-course analysis of hepcidin, serum
iron, and plasma cytokine levels in humans injected with LPS.
Blood. 106:1864–1866. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nemeth E, Valore EV, Territo M, Schiller
G, Lichtenstein A and Ganz T: Hepcidin, a putative mediator of
anemia of inflammation, is a type II acute-phase protein. Blood.
101:2461–2463. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nemeth E, Rivera S, Gabayan V, Keller C,
Taudorf S, Pedersen BK and Ganz T: IL-6 mediates hypoferremia of
inflammation by inducing the synthesis of the iron regulatory
hormone hepcidin. J Clin Invest. 113:1271–1276. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lee P, Peng H, Gelbart T, Wang L and
Beutler E: Regulation of hepcidin transcription by interleukin-1
and interleukin-6. Proc Natl Acad Sci USA. 102:1906–1910. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pelliniemi TT, Irjala K, Mattila K, Pulkki
K, Rajamäki A, Tienhaara A, Laakso M and Lahtinen R: Immunoreactive
interleukin-6 and acute phase proteins as prognostic factors in
multiple myeloma. Finnish Leukemia Group Blood. 85:765–771.
1995.PubMed/NCBI
|
|
19
|
Sharma S, Nemeth E, Chen YH, Goodnough J,
Huston A, Roodman GD, Ganz T and Lichtenstein A: Involvement of
hepcidin in the anemia of multiple myeloma. Clin Cancer Res.
14:3262–3267. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lee SH, Jeong SH, Park YS, Hwang JH, Kim
JW, Kim N and Lee DH: Serum prohepcidin levels in chronic hepatitis
C, alcoholic liver disease, and nonalcoholic fatty liver disease.
Korean J Hepatol. 16:288–294. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jaroszewicz J, Rogalska M, Flisiak I and
Flisiak R: Successful antiviral therapy is associated with a
decrease of serum prohepcidin in chronic hepatitis C. World J
Gastroenterol. 16:1747–1752. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shinzato T, Abe K, Furusu A, Harada T,
Shinzato K, Miyazaki M and Kohno S: Serum pro-hepcidin level and
iron homeostasis in Japanese dialysis patients with erythropoietin
(EPO)-resistant anemia. Med Sci Monit. 14:CR431–CR437.
2008.PubMed/NCBI
|
|
23
|
Durie BG and Salmon SE: A clinical staging
system for multiple myeloma. Correlation of measured myeloma cell
mass with presenting clinical features, response to treatment, and
survival. Cancer. 36:842–854. 1975. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Greipp PR, San Miguel J, Durie BG, Crowley
JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H,
Kyle RA, et al: International staging system for multiple myeloma.
J Clin Oncol. 23:3412–3420. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Roe MA, Spinks C, Heath AL, Harvey LJ,
Foxall R, Wimperis J, Wolf C and Fairweather-Tait SJ: Serum
prohepcidin concentration: no association with iron absorption in
healthy men; and no relationship with iron status in men carrying
HFE mutations, hereditary haemochromatosis patients undergoing
phlebotomy treatment, or pregnant women. Br J Nutr. 97:544–549.
2007. View Article : Google Scholar
|
|
26
|
Hadley KB, Johnson LK and Hunt JR: Iron
absorption by healthy women is not associated with either serum or
urinary prohepcidin. Am J Clin Nutr. 84:150–155. 2006.PubMed/NCBI
|
|
27
|
Young MF, Glahn RP, Ariza-Nieto M, Inglis
J, Olbina G, Westerman M and O’Brien KO: Serum hepcidin is
significantly associated with iron absorption from food and
supplemental sources in healthy young women. Am J Clin Nutr.
89:533–538. 2009.PubMed/NCBI
|
|
28
|
Katodritou E, Ganz T, Terpos E, Verrou E,
Olbina G, Gastari V, Hadjiaggelidou C, Varthaliti M, Georgiadou S,
Westerman M and Zervas K: Sequential evaluation of serum hepcidin
in anemic myeloma patients: study of correlations with myeloma
treatment, disease variables, and anemia response. Am J Hematol.
84:524–526. 2009. View Article : Google Scholar
|
|
29
|
Maes K, Nemeth E, Roodman GD, Huston A,
Esteve F, Freytes C, Callander N, Katodritou E, Tussing-Humphreys
L, Rivera S, et al: In anemia of multiple myeloma, hepcidin is
induced by increased bone morphogenetic protein 2. Blood.
116:3635–3644. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pigeon C, Ilyin G, Courselaud B, Leroyer
P, Turlin B, Brissot P and Loréal O: A new mouse liver-specific
gene, encoding a protein homologous to human antimicrobial peptide
hepcidin, is overexpressed during iron overload. J Biol Chem.
276:7811–7819. 2001. View Article : Google Scholar
|
|
31
|
Oustamanolakis P, Koutroubakis IE,
Messaritakis I, Malliaraki N, Sfiridaki A and Kouroumalis EA: Serum
hepcidin and prohepcidin concentrations in inflammatory bowel
disease. Eur J Gastroenterol Hepatol. 23:262–268. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Taes YE, Wuyts B, Boelaert JR, De Vriese
AS and Delanghe JR: Prohepcidin accumulates in renal insufficiency.
Clin Chem Lab Med. 42:387–389. 2004.PubMed/NCBI
|
|
33
|
Cherng NC, Asal NR, Kuebler JP, Lee ET and
Solanki D: Prognostic factors in multiple myeloma. Cancer.
67:3150–3156. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sakamori R, Takehara T, Tatsumi T,
Shigekawa M, Hikita H, Hiramatsu N, Kanto T and Hayashi N: STAT3
signaling within hepatocytes is required for anemia of inflammation
in vivo. J Gastroenterol. 45:244–248. 2010. View Article : Google Scholar : PubMed/NCBI
|
